Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Retained Earnings (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Retained Earnings readings, the most recent being -$1.4 million for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 5.68% to -$1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.4 million, a 5.68% decrease, with the full-year FY2024 number at -$1.4 million, down 10.71% from a year prior.
  • Retained Earnings hit -$1.4 million in Q3 2025 for Goldenwell Biotech, down from -$1.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$54810.0 in Q1 2021 to a low of -$1.4 million in Q3 2025.
  • Median Retained Earnings over the past 5 years was -$1.2 million (2023), compared with a mean of -$853217.5.
  • Biggest five-year swings in Retained Earnings: plummeted 1598.76% in 2021 and later decreased 5.68% in 2025.
  • Goldenwell Biotech's Retained Earnings stood at -$125690.0 in 2021, then plummeted by 783.75% to -$1.1 million in 2022, then dropped by 10.57% to -$1.2 million in 2023, then dropped by 10.71% to -$1.4 million in 2024, then dropped by 3.5% to -$1.4 million in 2025.
  • The last three reported values for Retained Earnings were -$1.4 million (Q3 2025), -$1.4 million (Q2 2025), and -$1.4 million (Q1 2025) per Business Quant data.